Behind The Labs

For another Behind the Labs episode, we talked about five studies exploring some pretty unexpected connections in biology—from how cells survive severe tissue damage and how that could relate to cancer treatment resistance, to whether blood thinners might also influence cognitive decline in people with Alzheimer’s and AFib. We also looked at major molecular changes happening in the aging brain during midlife, how a protein called Menin in the hypothalamus may influence aging throughout the body, and how accelerated biological aging in younger generations is associated with a higher risk of early-onset cancer. 

The five studies explored how everyday substances, medications, and biological targets can have unexpected effects on human health. They looked at caffeine and cellular aging, sugary drinks and gastric cancer, semaglutide and respiratory disease, GPR133 and osteoporosis, and a DNA-based treatment for high cholesterol. Although the topics are different, each study identified a biological mechanism that could potentially be used to improve health or better understand disease.

Together, the studies also show the importance of distinguishing promising research from proven medical treatments. Several findings came from animal models or observational data, meaning they provide important clues but do not establish cause and effect or guarantee that the same results will occur in humans. Overall, the research highlights how understanding cellular pathways can reveal unexpected connections between common exposures, medications, and disease.

Overall, we found the following:

• ☕ Caffeine: May activate AMPK, a cellular pathway involved in energy balance, stress responses, and aging.
• 🥤 Sugary drinks: Daily consumption was associated with a substantially higher risk of gastric cancer, although causation remains unproven.
• 💉 Semaglutide: Was associated with nearly 40% fewer asthma attacks, suggesting possible benefits beyond diabetes and weight loss.
• 🦴 GPR133: Activating this receptor with AP503 strengthened bones in mice and could represent a future osteoporosis treatment target.
• 🧬 PCSK9 DNA therapy: A single injection reduced cholesterol by 47% in mice, showing potential for a new gene-targeting approach to cholesterol treatment.

Today on Behind The Labs, we're diving into four stories reshaping how we think about the body and brain. First, we're debunking a 50-year-old myth: Linus Pauling's vitamin C megadose theory doesn't hold up against modern meta-analyses, which show at best a modest reduction in severe cold symptoms — not prevention. Then, we head into the operating room, where a new "double-punch" nanoparticle platform is helping surgeons see and destroy glioblastoma cells beyond what the eye or scalpel can reach, producing 100% survival in treated mice. From there, we trace how childhood trauma physically reshapes the brain — researchers have identified an enzyme, SETD7, that leaves a molecular "scar" on DNA packaging, priming stress genes to fire more easily decades later, and remarkably, they were able to block it. We'll also unpack a compound called TOFA that helps the body burn fat and preserve muscle simultaneously, offering a promising complement to GLP-1 drugs like Ozempic. And finally, we ask: could learning a new language be the secret to a younger brain? New research suggests multilingual speakers may have brains up to 13 years younger than their monolingual peers. Four studies, one throughline: the brain and body are far more malleable — and far more responsive to what we do to them — than we often assume.

In this episode of Behind The Labs, we opened with adolescence: UC San Diego followed more than 11,000 kids in the ABCD Study from ages 9 and 10 through 16 and 17, verifying cannabis exposure with hair, urine, and saliva rather than trusting self-report, and found that teens who started using didn't decline — they stopped improving, with memory, attention, language, and processing speed flattening out while their peers kept climbing, with THC looking like the driver. From there we went to the University of Zurich, where researchers overturned a textbook rule by watching living mouse brains for weeks and discovering a population of regenerative astrocytes that repair damaged tissue in a genuinely bizarre way — dividing and then sending newly formed daughter-cell nuclei gliding long distances through their own extensions to reknit the network from the inside. Next we got into why deep brain stimulation actually works for Parkinson's: a team from Cologne, Düsseldorf, Harvard, and Charité recorded from implanted electrodes and MEG simultaneously across 50 patients and 100 hemispheres, and found the subthalamic-to-frontal-cortex network communicates in the high beta band, 20 to 35 Hz, with connection strength tracking how much patients' motor symptoms improved — a possible route to tuning DBS by network instead of trial and error. And we closed in the brain's plumbing, where a University of Rochester team used a physics-informed AI to pull fluid velocities out of MRI for the first time and found the glymphatic system clears waste along two routes at wildly different speeds — a few microns per second near the surface, roughly 50 times slower deep in the tissue — with the long-term goal of screening people for sluggish circulation before Alzheimer's ever appears.

In this episode we looked at how cancer's own super-enhancer-driven growth program physically snaps its DNA, creating repeated break-and-repair cycles that may generate the mutations fueling tumor evolution. We then covered EPS8, an aging protein that hyperactivates RAC signaling and drives the toxic protein aggregation behind Huntington's and ALS — knocking it down cleared aggregates in both worms and human cells. Third, an antisense oligonucleotide targeting the glycine transporter SLC6A20 restored NMDA receptor function and social behavior in adult autism model mice, with the same effect reproduced in human cortical organoids. We also broke down a 150,000-person, 30-year cohort showing that just 90 to 120 minutes of strength training a week tracks with 13% lower all-cause mortality, and up to 45% when paired with regular aerobic exercise. Finally, we ended on evolution: Indigenous Andeans carry more copies of the starch-digesting AMY1 gene than any known population, a signature selected for after potato farming began roughly 10,000 years ago.

In this episode of Behind the Labs, we explore four exciting studies that showcase how advances in artificial intelligence, neuroscience, metabolism, and gene editing are shaping the future of medicine. We discuss new research revealing that popular AI-powered calorie tracking apps significantly underestimate calorie and fat intake, highlighting the importance of using these tools cautiously. We also examine how a single dose of psilocybin may temporarily reshape brain activity, increase psychological insight, and improve well-being, offering new clues about its potential role in treating depression and other mental health disorders.

The episode also covers a promising obesity treatment discovered using artificial intelligence—a naturally occurring peptide called BRP that produced Ozempic-like weight loss in animal studies while avoiding many common side effects. We then dive into groundbreaking neuroscience research showing that autism-like symptoms caused by prenatal inflammation in mice could be rapidly improved by targeting brain signaling pathways, suggesting that the adult brain may be more adaptable than previously believed. F

This episode dives into four major discoveries reshaping how scientists understand brain and muscle aging. We start with a Duke-NUS study showing exercise fights age-related muscle loss by correcting a molecular imbalance driven by the gene DEAF1, which disrupts the cell's ability to clear damaged proteins as we age. From there we shift to the brain, exploring a King's College London discovery of "karyoptosis," a newly identified cell death process that may explain how toxic protein buildup kills neurons in Alzheimer's and frontotemporal dementia, pointing to a specific molecular target (p38 MAP kinase and LaminB1) for future therapies.

We then turn to sleep, unpacking UC Berkeley research that maps the brain circuitry linking deep sleep to growth hormone release, revealing a feedback loop between hormone levels and the brain's alertness center that helps explain why poor sleep disrupts growth, metabolism, and recovery. Finally, we explore the mystery of cognitive resilience, discussing a Netherlands Institute for Neuroscience study on why some people stay mentally sharp despite Alzheimer's pathology in their brains, with early evidence pointing to rare "immature neurons" that behave differently in resilient individuals, not by growing in number, but by activating survival programs that may help protect surrounding brain tissue. Together, these studies highlight a common thread: aging and disease resistance often come down to how cells manage stress, repair, and communication rather than simple decline.

In this episode of Behind The Labs, we broke down five major research studies pushing the boundaries of neuroscience and medicine. We covered Northwestern's experimental drug NU-9, which may prevent Alzheimer's before symptoms ever appear by targeting a newly identified toxic amyloid subtype. We then talked about Japanese researchers engineering a supercharged vitamin K compound that can actually regenerate lost neurons — a first for the field. Johns Hopkins blew our minds with pea-sized lab-grown brains that can distinguish schizophrenia from bipolar disorder with 92% accuracy, opening the door to personalized psychiatric treatment. On the prevention side, a massive meta-analysis confirmed that eating legumes and soy foods daily can cut hypertension risk by nearly 30%, and NYU researchers found a simple blood test that detects depression through accelerated immune cell aging — before you even feel it. The big theme across all of it: medicine is shifting from treating disease after the damage is done to catching and stopping it years earlier.

Today at Behind The Labs, we’re looking at five recent health-related studies that sound very different on the surface: exercise, dementia, Alzheimer’s disease, semaglutide, and creatine.

But there’s a common theme across all of them: health is not just about one organ, one habit, or one simple cause. The brain affects endurance. Speech may reveal cognitive decline. Blood vessels may shape Alzheimer’s disease. Weight-loss medication may help older adults but still requires caution. Creatine may support more than muscle.

In this episode of Behind the Labs, we explore cutting-edge research that’s reshaping how we understand sleep, brain health, and chronic pain. We start with a clinical trial on solriamfetol, a wake-promoting drug showing promising results for early morning shift workers—a group often overlooked despite facing major circadian rhythm disruptions. The findings highlight how aligning (or misaligning) with our biological clock can dramatically impact alertness, performance, and overall well-being. We also dive into a Lancet-published study on sulthiame, a potential game-changer for obstructive sleep apnea, offering hope for patients who struggle with traditional CPAP therapy by directly improving breathing regulation during sleep.

Beyond sleep, we unpack research on lifelong cognitive engagement and its link to reduced Alzheimer’s risk, emphasizing the idea of “cognitive reserve” and how habits like reading and learning may delay neurodegeneration by years. Finally, we discuss groundbreaking neuroscience uncovering a brain circuit in the insular cortex that may actively sustain chronic pain—challenging the notion that pain simply lingers after injury. Together, these studies reveal how deeply interconnected our brain, behavior, and biology are, while pointing toward innovative treatments that could transform patient care in the future.